BioCryst Receives Special Protocol Assessment for Fodosine
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) under the FDA's Special Protocol Assessment (SPA) process for the design of its planned pivotal clinical trial of the oral formulation of the company's le...BioCryst Provides Fodosine(TM) Update
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today provided an update regarding the company's development programs for Fodosine(TM). Phase IIb Trial in T-ALL ...Summary of BIOCRYST PHARMACEUTICALS INC - Yahoo! Finance
Fodosine™ is currently in various stages of clinical development in multiple ... In February 2006, we licensed Fodosine™ to Mundipharma for the development and ...International Approvals: Remicade, Fodosine, Sprycel
: The EU has approved a label extension for infliximab injection (Remicade) and orphan drug status for fodosine (Fodosine); Canada has approved dasatinib tablets ...Press Release: Biocryst Pharmaceuticals Places Hold on Trial of IV ...
Press Release: Biocryst Pharmaceuticals Places Hold on Trial ... Assay data do not suggest any decrease in the potency of the Fodosine(TM) active drug product. ...EMEA Grants Orphan Drug Designation to BioCryst's Fodosine(TM) for the ...
today announced that Fodosine(TM) has been granted orphan status for the ... Fodosine(TM) is a transition-state analog inhibitor of the target enzyme purine ...Biocryst Pharmaceuticals Initiates Pivotal Fodosine(TM) Phase IIb ...
Those data indicated Fodosine(TM) is safe, well tolerated and effective as a ... Fodosine(TM) is a transition-state analog inhibitor of the target enzyme purine ...